Global Gene Therapy Market Analysis

Introduction

In the past few years, gene therapy has come a long way to become one of the most sought after methods to develop a treatment. Despite being at a nascent stage in terms of revenue generation, the gene therapy market holds tremendous growth potential. As per a new estimation, carried out in our latest study, the global gene therapy industry will reach US$ 325 Million by the end of 2015 as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.

According to our new research report, “Global Gene Therapy Market Analysis”, major market players are developing gene therapy-based products using the adenoviral vectors. We found that the majority of the drugs using the adenoviral vectors are in the phase I/II clinical stages. In this context, the study provides a comprehensive overview of the different vectors in the gene therapy market, and talks about major products in the pipeline and their development phase.

Through in-depth and prudent analysis of the developments taking place at the global level, we have observed that the market is presently dominated by oncology applications. A large number of companies and academic institutions are developing products, targeting different types of cancer. Other therapeutic areas, such as genetic disorder and neurological diseases are also occupying enough space in the product pipeline. An effective analysis of the key therapeutic areas has been included in our report.

The report studies how trends and drivers, including gene silencing, advanced therapies and increased use of viral vectors, among others, will propel the industry's growth. The study of key geographies revealed that the US, Europe, Canada, China, and Japan are the major markets exhibiting healthy growth rates. It also highlighted that the highest growth rate in the developing countries' gene therapy market is likely to be observed for the treatment of cancer, followed by infectious diseases, like AIDS. Our comprehensive research report also looks into the profiles of key market players, including AnGes MG and Ark Therapeutics, to provide an objective view of the global gene therapy market to clients.

Table of Contents

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction

• 3.1. Classification of Gene Therapy Techniques
• 3.2. Physical Methods of Gene Transfer
  • 3.2.1. Electroporation
  • 3.2.2. Hydrodynamic
  • 3.2.3. Microinjection
  • 3.2.4. Particle Bombardment
  • 3.2.5. Ultrasound-mediated Transfection
• 3.3. Vectors for Gene Therapy
  • 3.3.1. Adenoviral Vectors
  • 3.3.2. Adeno-associated Virus Vectors
  • 3.3.3. Retroviral Vectors
  • 3.3.4. Lentiviral Vectors
  • 3.3.5. Plasmid DNA

4. Industry Trends and Drivers

• 4.1. Gene Silencing: Gaining Momentum
• 4.2. Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
• 4.3. Immunodeficiency Syndromes: The Focus of Gene Therapy
• 4.4. Expanded Use of Viral Vectors
• 4.5. Nanotechnology: Empowering Gene Therapy
• 4.6. Gene Therapy: A New Hope to Treat Blindness

5. Industry Overview

• 5.1. Market Size and Growth
• 5.2. By Application
  • 5.2.1 Oncology
    • 5.2.1.1. Key Approaches
    • 5.2.1.2. Recent Advancements
  • 5.2.2 Infectious Diseases
    • 5.2.2.1. Key Approaches
    • 5.2.2.2. Recent Advancements
  • 5.2.3 Genetic Disorders
    • 5.2.3.1. Key Approaches
    • 5.2.3.2. Recent Advancements
  • 5.2.4 Cardiovascular Disorders
    • 5.2.4.1. Key Approaches
    • 5.2.4.2. Recent Advancements
  • 5.2.5 Diabetes Mellitus
    • 5.2.5.1. Key Approaches
    • 5.2.5.2. Recent Advancements
  • 5.2.6 Neurological Disorders
    • 5.2.6.1. Key Approaches
    • 5.2.6.2. Recent Advancements
• 5.3. Key Geographical Markets
  • 5.3.1 US
    • 5.3.1.1. Regulatory Landscape
    • 5.3.1.2. Recent Advancements
  • 5.3.2 Europe
    • 5.3.2.1. Regulatory Landscape
    • 5.3.2.2. Recent Advancements
  • 5.3.3 Australia
    • 5.3.3.1. Regulatory Landscape
    • 5.3.3.2. Recent Advancements
  • 5.3.4 Canada
    • 5.3.4.1. Regulatory Landscape
    • 5.3.4.2. Recent Advancements
  • 5.3.5 Israel
    • 5.3.5.1. Regulatory Landscape
    • 5.3.5.2. Recent Advancements
  • 5.3.6 Japan
    • 5.3.6.1. Regulatory Landscape
    • 5.3.6.2. Recent Advancements
  • 5.3.7 China
    • 5.3.7.1. Regulatory Landscape
    • 5.3.7.2. Recent Advancements
  • 5.3.8 India
    • 5.3.8.1. Regulatory Landscape
    • 5.3.8.2. Recent Advancements
• 5.4. Advanced Gene Therapy Drugs
  • 5.4.1. Glybera
  • 5.4.2. Collategene
  • 5.4.3. Allovectin-7
  • 5.4.4. Generx

6. Research & Development

• 6.1. Ongoing Gene Therapy Clinical Trials
• 6.2. Vectors in Ongoing Gene Therapy Clinical Trials

7. Key Players Analysis

• 7.1. AnGes MG, Inc
• 7.2. Ark Therapeutics
• 7.3. Amsterdam Molecular Therapeutics
• 7.4. Ceregene, Inc
• 7.5. Cobra Biologics
• 7.6. GenVec, Inc
• 7.7. Genzyme Corporation
• 7.8. Neurologix, Inc
• 7.9. Vical, Inc
• 7.10. Oxford BioMedica

• Figure 5-1: Global - Gene Therapy Market (Million US$), 2011 & 2015
• Figure 5-2: US - Number of New Cell Therapy and Gene Therapy Products Submission to FDA (2003-2010)
• Figure 5-3: Japan - Evaluation System of Gene Therapy Clinical Trial
• Figure 6-1: Global - Use of Vectors in Gene Therapy Trials (%)

• Table 5-1: Prevalence of Key Single Gene Disorders
• Table 5-2: Vectors Used for Cardiovascular Gene Transfer
• Table 5-3: Number of Approved Gene Therapy Protocols
• Table 5-4: China - Key Players and their Products in Gene Therapy
• Table 5-5: Key Advanced Gene Therapy Drugs
• Table 5-6: Unmet Need Analysis for Collategene
• Table 5-7: Potential Market Size of Allovectin-7 in the US and EU (Million US$)
• Table 5-8: Potential Market Size of Generx (Million US$)
• Table 6-1: Key Gene Therapy Clinical Trials

Global Gene Therapy Market Analysis published by RNCOS E-Services Pvt. Ltd. in April 1, 2012. This report consists of 120 Pages and the price starts from US $ 1200.

The contents of this page may be different from the latest version. Please contact us for details.